InfusionShots vs. InfusionDrops
(Subcutaneous vs. sublingual immunotherapy)




Method of Administration

Injected into arm using small needle initially 1-3 times/week with frequency being reduced to monthly after “build-up” phase. Administered in physician’s office with a 30-minute post-injection observation period. Liquid is placed under tongue three times daily and held there for several minutes, then swallowed. May be administered at home.


Reduces allergy and asthma symptoms in 85-90% of patients. May prevent development of asthma in some patients. Patients with a single allergen benefit. Not as effective in patients allergic to multiple allergens. Only a few studies have compared these two methods.

FDA Approved?

 Yes, both the allergy mixture and method of administration are FDA approved.  No, the allergy mixture is the same, but no standard has been set for preparation, concentration, dosing or schedule. Therefore it is considered investigational.

Insurance Coverage?

 Yes  No

Duration of

 Patient will receive monthly injections for 3-5 years. Patient will administer daily drops for 3-5 years for best results, although research is still needed to prove the best duration and dosing.

Adverse Reactions

 Local reactions at injection site may occur. Although rare, anaphylaxis can occur. Itching of mouth, tongue and ears; swelling of mouth and tongue; and gastrointestinal symptoms such as nausea, vomiting and diarrhea may occur.


 A well-defined, long-term tolerance upon completion of immunotherapy occurs. Due to conflicting data, tolerance upon completion is unknown. Loss of tolerance upon completing immunotherapy is common.